PMID: 11929130Apr 4, 2002Paper

The origin of CD95-gene mutations in B-cell lymphoma

Trends in Immunology
Markus MüschenRalf Küppers

Abstract

CD95 (Apo-1/Fas) is crucial for the negative selection of B cells within the germinal center (GC). Impairment of CD95-mediated apoptosis results in defective affinity maturation and the persistence of autoreactive B-cell clones. CD95 was defined recently as a tumor-suppressor gene and is silenced in many tumor entities. In contrast to other malignancies, in GC-derived B-cell lymphomas, inactivation of the CD95 gene is often a result of deleterious mutations. Such mutations occur also at a low frequency in normal GC, but not naive, B cells. We propose that CD95 mutations in B-cell lymphomas originate from the GC reaction and are introduced most probably as targeting errors of the somatic hypermutation machinery, which bears--besides its physiological role--an inherent risk of malignant transformation and the persistence of autoreactive B-cell specificities.

References

Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·K NagataJ Hurwitz
Apr 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·T GoossensR Küppers
May 29, 1998·Immunological Reviews·U KleinR Küppers
Jun 10, 1998·The Journal of Experimental Medicine·W F DavidsonT N Fredrickson
Aug 29, 1998·British Journal of Haematology·C BeltingerK M Debatin
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·L PasqualucciR Dalla-Favera
Jun 11, 1999·The American Journal of Pathology·M S ShinS H Lee
Jun 25, 1999·Cell Death and Differentiation·W Abdel-RahmanA Wyllie
Nov 24, 1999·The New England Journal of Medicine·R KüppersK Rajewsky
Jan 19, 2000·The Journal of Experimental Medicine·M MüschenR Küppers
Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Jan 29, 2000·Immunology·M MüschenM W Beckmann
Sep 23, 2000·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·M MüschenM W Beckmann
Dec 20, 2000·The Journal of Experimental Medicine·M MüschenR Küppers
Feb 13, 2001·Experimental Hematology·G Rozenfeld-GranotG Rechavi
Feb 22, 2001·The Journal of Experimental Medicine·A HenninoT Defrance
Apr 6, 2001·International Journal of Cancer. Journal International Du Cancer·M MüschenM W Beckmann
Dec 12, 2001·Trends in Immunology·M van EijkC de Groot

❮ Previous
Next ❯

Citations

Jun 11, 2005·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Lisa Oliver, François M Vallette
Jan 1, 2004·The Lancet Oncology·Roman K ThomasVolker Diehl
Oct 18, 2002·Immunology·Liliana Guzman-RojasHector Martinez-Valdez
Oct 2, 2004·The New England Journal of Medicine·Rita ClementiMarco Bregni
Apr 14, 2004·The Journal of Experimental Medicine·Stephan MathasBernd Dörken
Aug 23, 2002·Current Opinion in Oncology·Rajani Ravi, Atul Bedi
Jun 30, 2011·PLoS Biology·Sébastien TauzinPatrick Legembre
Mar 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·Melinda S GordonRandolph Wall
Nov 2, 2011·Cellular and Molecular Life Sciences : CMLS·Sébastien TauzinPatrick Legembre
Jan 1, 2003·The American Journal of Pathology·Ewerton M MaggioSibrand Poppema
Nov 4, 2008·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Lorena Martinez-GamboaThomas Dörner
Jul 13, 2005·European Journal of Haematology. Supplementum·Ralf KüppersMartin-Leo Hansmann
May 3, 2003·Annals of the New York Academy of Sciences·Ralf Küppers
Mar 30, 2010·British Journal of Haematology·Kay Klapproth, Thomas Wirth
Oct 8, 2003·Hematology·Kostas StamatopoulosAchilles Anagnostopoulos
May 7, 2008·Journal of Cellular Biochemistry·Jessica PlatiRoya Khosravi-Far
May 2, 2014·Biochimica Et Biophysica Acta·Amélie FouquéPatrick Legembre
May 10, 2007·Leukemia & Lymphoma·Vanesa SchollIlana Zalcberg Renault
May 23, 2006·Hematological Oncology·Jettie J F MurisJoost J Oudejans
Oct 23, 2004·Cell Death and Differentiation·B C BarnhartM E Peter
Oct 28, 2019·Cancers·Zhang'e ChooZhi Xiong Chen
Apr 16, 2020·Expert Review of Hematology·Marijana NesicKaren Dybkær
May 16, 2020·Immunological Reviews·Michelle A Mintz, Jason G Cyster
Feb 23, 2020·Immunology and Cell Biology·Clara Young, Robert Brink
Feb 18, 2017·Journal of Investigative Medicine High Impact Case Reports·Moaath Mustafa AliHetty E Carraway
Nov 25, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Mohamed AliPamela J Fink

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.